Myricetin, a natural inhibitor of CD147, increases sensitivity of cisplatin in ovarian cancer

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–1253. doi: 10.1016/S0140-6736(18)32552-2
   PubMed Web of Science ®Google Scholar
• Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020;75(11):2829–2845. doi: 10.1111/all.14429
   PubMed Web of Science ®Google Scholar
• Biswas C, Zhang Y, DeCastro R, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995;55(2):434–439.
   PubMed Web of Science ®Google Scholar
• Lucke JN. Malignant hyperthermia in a parturient Poland China sow. Br J Anaesth. 1977;49(10):1070. doi: 10.1093/bja/49.10.1070
   PubMed Web of Science ®Google Scholar
• Le Floch R, Chiche J, Marchiq I, et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A. 2011;108(40):16663–16668. doi: 10.1073/pnas.1106123108
   PubMed Web of Science ®Google Scholar
• Kay WW, Cameron MJ. Transport of C4-dicarboxylic acids in salmonella typhimurium. Arch Biochem Biophys. 1978;190(1):281–289. doi: 10.1016/0003-9861(78)90277-1
   PubMed Web of Science ®Google Scholar
• Rodrigo R, Thielemann L, Olea M, et al. Effect of ethanol ingestion on renal regulation of water and electrolytes. Arch Med Res. 1998;29(3):209–218.
   PubMed Web of Science ®Google Scholar
• Tang Y, Nakada MT, Kesavan P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005;65(8):3193–3199. doi: 10.1158/0008-5472.CAN-04-3605
   PubMed Web of Science ®Google Scholar
• Bougatef F, Menashi S, Khayati F, et al. EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2. PloS One. 2010;5(8):e12265. doi: 10.1371/journal.pone.0012265
   PubMed Web of Science ®Google Scholar
• Zhou S, Liao L, Chen C, et al. CD147 mediates chemoresistance in breast cancer via ABCG2 by affecting its cellular localization and dimerization. Cancer Lett. 2013;337(2):285–292. doi: 10.1016/j.canlet.2013.04.025
   PubMed Web of Science ®Google Scholar
• Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology. 2007;45(2):269–276. doi: 10.1002/hep.21465
   PubMed Web of Science ®Google Scholar
• Fu ZG, Wang L, Cui HY, et al. A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells. Oncotarget. 2016;7(8):9429–9447. doi: 10.18632/oncotarget.6990
   PubMedGoogle Scholar
• Fu ZG, Wang Y, Wang S, et al. Synthesis and evaluation of a novel Small-molecule Compound as an anticancer inhibitor of CD147. Biomed Environ Sci. 2019;32(9):673–686. doi: 10.3967/bes2019.086
   PubMed Web of Science ®Google Scholar
• Guo N, Miao R, Gao X, et al. Shikonin inhibits proliferation and induces apoptosis in glioma cells via downregulation of CD147. Mol Med Rep. 2019;19(5):4335–4343. doi: 10.3892/mmr.2019.10101
   PubMed Web of Science ®Google Scholar
• Javed Z, Khan K, Herrera-Bravo J, et al. Myricetin: targeting signaling networks in cancer and its implication in chemotherapy. Cancer Cell Int. 2022;22(1):239. doi: 10.1186/s12935-022-02663-2
   PubMed Web of Science ®Google Scholar
• Lee KW, Kang NJ, Rogozin EA, et al. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis. 2007;28(9):1918–1927. doi: 10.1093/carcin/bgm110
   PubMed Web of Science ®Google Scholar
• Kumamoto T, Fujii M, Hou DX. Myricetin directly targets JAK1 to inhibit cell transformation. Cancer Lett. 2009;275(1):17–26. doi: 10.1016/j.canlet.2008.09.027
   PubMed Web of Science ®Google Scholar
• Kumamoto T, Fujii M, Hou DX. Akt is a direct target for myricetin to inhibit cell transformation. Mol Cell Biochem. 2009;332(1–2):33–41. doi: 10.1007/s11010-009-0171-9
   PubMed Web of Science ®Google Scholar
• Phillips PA, Sangwan V, Borja-Cacho D, et al. Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer Lett. 2011;308(2):181–188. doi: 10.1016/j.canlet.2011.05.002
   PubMed Web of Science ®Google Scholar
• Sun Q, Liu Q, Zhou X, et al. Flavonoids regulate tumor-associated macrophages - from structure-activity relationship to clinical potential. Pharmacol Res. 2022;184:106419. doi: 10.1016/j.phrs.2022.106419
   PubMed Web of Science ®Google Scholar
• Pahk K, Noh H, Joung C, et al. A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation. J Transl Med. 2019;17(1):274. doi: 10.1186/s12967-019-2024-y
   PubMed Web of Science ®Google Scholar
• Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 2001;61(5):2276–2281.
   PubMed Web of Science ®Google Scholar
• Min X, Zhang X, Li Y, et al. HSPA12A unstabilizes CD147 to inhibit lactate export and migration in human renal cell carcinoma. Theranostics. 2020;10(19):8573–8590. doi: 10.7150/thno.44321
   PubMed Web of Science ®Google Scholar
• Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304. doi: 10.3322/caac.21559
   PubMed Web of Science ®Google Scholar
• Tavsan Z, Kayali HA. Flavonoids showed anticancer effects on the ovarian cancer cells: involvement of reactive oxygen species, apoptosis, cell cycle and invasion. Biomed Pharmacother. 2019;116:109004. doi: 10.1016/j.biopha.2019.109004
   PubMed Web of Science ®Google Scholar
• Xu Y, Xie Q, Wu S, et al. Myricetin induces apoptosis via endoplasmic reticulum stress and DNA double-strand breaks in human ovarian cancer cells. Mol Med Rep. 2016;13(3):2094–2100. doi: 10.3892/mmr.2016.4763
   PubMed Web of Science ®Google Scholar
• Zheng AW, Chen YQ, Zhao LQ, et al. Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells. Oncol Lett. 2017;13(6):4974–4978. doi: 10.3892/ol.2017.6031
   PubMed Web of Science ®Google Scholar
• Huang H, Chen AY, Ye X, et al. Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway. Int J Oncol. 2015;47(4):1494–1502. doi: 10.3892/ijo.2015.3133
   PubMed Web of Science ®Google Scholar
• Wang W, Li J, Tan J, et al. Endonuclease G promotes autophagy by suppressing mTOR signaling and activating the DNA damage response. Nat Commun. 2021;12(1):476. doi: 10.1038/s41467-020-20780-2
   PubMed Web of Science ®Google Scholar
• Afonso J, Santos LL, Miranda-Goncalves V, et al. CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance. Mol Carcinog. 2015;54(11):1451–1466. doi: 10.1002/mc.22222
   PubMed Web of Science ®Google Scholar
• Wang B, Xu YF, He BS, et al. RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensitivity to cisplatin in SGC7901 cells in vitro. J Exp Clin Cancer Res. 2010;29(1):61. doi: 10.1186/1756-9966-29-61
   PubMedGoogle Scholar
• Wu B, Liu ZY, Cui J, et al. F-Box protein FBXO22 mediates polyubiquitination and degradation of CD147 to reverse cisplatin resistance of tumor cells. Int J Mol Sci. 2017;18(1):212. doi: 10.3390/ijms18010212
   PubMed Web of Science ®Google Scholar
• Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9–23. doi: 10.1016/j.ctrv.2006.09.006
   PubMed Web of Science ®Google Scholar
• Ma L, Cao X, Wang H, et al. Discovery of myricetin as a potent inhibitor of human flap endonuclease 1, which potentially can be used as sensitizing agent against HT-29 human colon cancer cells. J Agric Food Chem. 2019;67(6):1656–1665. doi: 10.1021/acs.jafc.8b05447
   PubMed Web of Science ®Google Scholar
• Kwok JM, Peck B, Monteiro LJ, et al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res. 2010;8(1):24–34. doi: 10.1158/1541-7786.MCR-09-0432
   PubMed Web of Science ®Google Scholar
• Tassi RA, Todeschini P, Siegel ER, et al. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. J Exp Clin Cancer Res. 2017;36(1):63. doi: 10.1186/s13046-017-0536-y
   PubMedGoogle Scholar
• Monteiro LJ, Khongkow P, Kongsema M, et al. The forkhead box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene. 2013;32(39):4634–4645. doi: 10.1038/onc.2012.491
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang Y, Wang Y, et al. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer. PloS One. 2014;9(5):e96989. doi: 10.1371/journal.pone.0096989
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zheng M, Liu Z, et al. CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer. Biochem Biophys Res Commun. 2020;528(1):62–70. doi: 10.1016/j.bbrc.2020.05.005
   PubMed Web of Science ®Google Scholar
• Huang H, Chen AY, Rojanasakul Y, et al. Dietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis. J Funct Foods. 2015;15:464–475. doi: 10.1016/j.jff.2015.03.051
   PubMed Web of Science ®Google Scholar
• Varela-Rodriguez L, Sanchez-Ramirez B, Hernandez-Ramirez VI, et al. Effect of gallic acid and myricetin on ovarian cancer models: a possible alternative antitumoral treatment. BMC Complement Med Ther. 2020;20(1):110. doi: 10.1186/s12906-020-02900-z
   PubMedGoogle Scholar
• Dobrzynska M, Napierala M, Florek E. Flavonoid nanoparticles: a promising approach for cancer therapy. Biomolecules. 2020;10(9). doi: 10.3390/biom10091268
   PubMed Web of Science ®Google Scholar
• Wang ZH, Ah KK, Zhang R, et al. Myricetin suppresses oxidative stress-induced cell damage via both direct and indirect antioxidant action. Environ Toxicol Pharmacol. 2010;29(1):12–18. doi: 10.1016/j.etap.2009.08.007
   PubMed Web of Science ®Google Scholar
• Das A, Majumder D, Saha C. Correlation of binding efficacies of DNA to flavonoids and their induced cellular damage. J Photochem Photobiol B. 2017;170:256–262. doi: 10.1016/j.jphotobiol.2017.04.019
   PubMed Web of Science ®Google Scholar
• Sahu SC, Gray GC. Interactions of flavonoids, trace metals, and oxygen: nuclear DNA damage and lipid peroxidation induced by myricetin. Cancer Lett. 1993;70(1–2):73–79. doi: 10.1016/0304-3835(93)90077-M
   PubMed Web of Science ®Google Scholar
• Laughton MJ, Halliwell B, Evans PJ, et al. Antioxidant and pro-oxidant actions of the plant phenolics quercetin, gossypol and myricetin. Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA. Biochem Pharmacol. 1989;38(17):2859–2865. doi: 10.1016/0006-2952(89)90442-5
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Wang L, Cline CJ, et al. Identification and characterization of human apurinic/apyrimidinic endonuclease-1 inhibitors. Biochemistry. 2012;51(31):6246–6259. doi: 10.1021/bi300490r
   PubMed Web of Science ®Google Scholar
• Lopez-Lazaro M, Martin-Cordero C, Toro MV, et al. Flavonoids as DNA topoisomerase I poisons. J Enzyme Inhib Med Chem. 2002;17(1):25–29. doi: 10.1080/14756360290011744
   PubMed Web of Science ®Google Scholar
• Halasi M, Gartel AL, Li J. Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage. PloS One. 2012;7(2):e31761. doi: 10.1371/journal.pone.0031761
   PubMed Web of Science ®Google Scholar
• Zhang P, Chen X, Zhang L, et al. POLE2 facilitates the malignant phenotypes of glioblastoma through promoting AURKA-mediated stabilization of FOXM1. Cell Death Dis. 2022;13(1):61. doi: 10.1038/s41419-021-04498-7
   PubMed Web of Science ®Google Scholar
• Yao S, Fan LY, Lam EW. The FOXO3-FOXM1 axis: a key cancer drug target and a modulator of cancer drug resistance. Semin Cancer Biol. 2018;50:77–89. doi: 10.1016/j.semcancer.2017.11.018
   PubMed Web of Science ®Google Scholar
• Jin C, Liu Z, Li Y, et al. PCNA-associated factor P15(PAF), targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients. Int J Cancer. 2018;143(11):2973–2984. doi: 10.1002/ijc.31800
   PubMed Web of Science ®Google Scholar
• Hassan SM, Khalaf MM, Sadek SA, et al. Protective effects of apigenin and myricetin against cisplatin-induced nephrotoxicity in mice. Pharm Biol. 2017;55(1):766–774. doi: 10.1080/13880209.2016.1275704
   PubMed Web of Science ®Google Scholar
• Qi X, Wang J, Fei F, et al. Myricetin-loaded nanomicelles protect against cisplatin-induced acute kidney injury by inhibiting the DNA damage-cGAS-STING signaling pathway. Mol Pharm. 2023;20(1):136–146. doi: 10.1021/acs.molpharmaceut.2c00520
   PubMedGoogle Scholar